Eli Lilly and Company
I · Analyse IA
En bref
Eli Lilly discovers, develops, manufactures, and sells prescription medicines globally. Their product portfolio spans diabetes drugs (Humalog, Mounjaro, Trulicity), obesity treatments (Zepbound), cancer therapies (Verzenio, Jaypirca), immunology drugs (Taltz, Olumiant), and Alzheimer's treatments (Kisubla). The company operates manufacturing facilities and research labs, and recently began licensing its AI drug discovery platform (TuneLab) to other biotech firms [Yahoo Finance].
Eli Lilly is a major pharmaceutical company with a $910.8 billion market cap [Yahoo Finance], known for developing drugs for diabetes, obesity, cancer, and immunology. The company is riding a massive wave of growth driven by its obesity and diabetes medications Mounjaro and Zepbound, which now generate roughly $13 billion combined per quarter [GuruFocus]. Recent positive clinical trial data and a $4.50 billion manufacturing expansion [Yahoo Finance] signal the company's commitment to this lucrative market, though this concentration creates significant execution risk.
Eli Lilly is in exceptional financial health, posting explosive growth and strong profitability metrics [Yahoo Finance].
Score Sentinellis
8.9/10
Financially healthy
Capitalisation boursière
$910.8B
Chiffre d'affaires (12 mois)
$65.2B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
Eli Lilly Expands TuneLab Access As AI Partnerships Shape R&D Outlook
Simply Wall St
- macro2026-05-20
Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines
Yahoo Finance
- macro2026-05-20
Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
Yahoo Finance
- macro2026-05-20
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Yahoo Finance
- macro2026-05-18
Supreme Court Ruling Puts Eli Lilly Medicaid Risks And Dividend In Focus
Simply Wall St
- macro2026-05-19
If You Hold This Healthcare ETF, You’re Losing Big
Yahoo Finance
Premium · gratuit avec tout compte
Extreme revenue concentration: Mounjaro and Zepbound now account for the majority of quarterly revenue at roughly $13 billion combined, meaning any manufacturing issues, safety concerns, or demand slowdown would directly threaten overall financial performance [GuruFocus]
Risques
5
Opportunités
5
Signaux d'alerte
3
Direction
10
22 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Eli Lilly and Company
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 5 risques, 5 opportunités et 3 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?